JP4352114B2 - 有益な効果を奏するアルギニンの投薬 - Google Patents
有益な効果を奏するアルギニンの投薬 Download PDFInfo
- Publication number
- JP4352114B2 JP4352114B2 JP2000511359A JP2000511359A JP4352114B2 JP 4352114 B2 JP4352114 B2 JP 4352114B2 JP 2000511359 A JP2000511359 A JP 2000511359A JP 2000511359 A JP2000511359 A JP 2000511359A JP 4352114 B2 JP4352114 B2 JP 4352114B2
- Authority
- JP
- Japan
- Prior art keywords
- substance
- arginine
- agent
- topical application
- delivery vehicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims description 13
- 230000009286 beneficial effect Effects 0.000 title abstract description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title description 20
- 239000004475 Arginine Substances 0.000 title description 19
- 229940079593 drug Drugs 0.000 title description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 86
- 239000000126 substance Substances 0.000 claims abstract description 80
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 53
- 229930064664 L-arginine Natural products 0.000 claims abstract description 50
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 50
- 238000010792 warming Methods 0.000 claims abstract description 32
- 201000001881 impotence Diseases 0.000 claims abstract description 17
- 241000282414 Homo sapiens Species 0.000 claims abstract description 16
- 230000035876 healing Effects 0.000 claims abstract description 11
- 230000000699 topical effect Effects 0.000 claims description 92
- 239000003981 vehicle Substances 0.000 claims description 86
- 239000003795 chemical substances by application Substances 0.000 claims description 81
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 72
- 150000003839 salts Chemical class 0.000 claims description 53
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 38
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- 239000011780 sodium chloride Substances 0.000 claims description 36
- 239000006071 cream Substances 0.000 claims description 31
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 29
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 24
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 24
- 239000002502 liposome Substances 0.000 claims description 23
- 208000025865 Ulcer Diseases 0.000 claims description 22
- 230000017531 blood circulation Effects 0.000 claims description 22
- 231100000397 ulcer Toxicity 0.000 claims description 22
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 21
- 230000003779 hair growth Effects 0.000 claims description 20
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 claims description 20
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 19
- 235000019743 Choline chloride Nutrition 0.000 claims description 19
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 19
- 229960003178 choline chloride Drugs 0.000 claims description 19
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 19
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 14
- 102000008186 Collagen Human genes 0.000 claims description 14
- 108010035532 Collagen Proteins 0.000 claims description 14
- 101800003906 Substance P Proteins 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 14
- 229920001436 collagen Polymers 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000835 fiber Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 12
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 claims description 12
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 12
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 12
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 12
- 235000014104 aloe vera supplement Nutrition 0.000 claims description 12
- 229960000541 cetyl alcohol Drugs 0.000 claims description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- 239000002480 mineral oil Substances 0.000 claims description 12
- 235000010446 mineral oil Nutrition 0.000 claims description 12
- 210000003899 penis Anatomy 0.000 claims description 12
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 12
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 12
- 229940113124 polysorbate 60 Drugs 0.000 claims description 12
- 230000001953 sensory effect Effects 0.000 claims description 12
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 12
- 229940031439 squalene Drugs 0.000 claims description 12
- 235000019155 vitamin A Nutrition 0.000 claims description 12
- 239000011719 vitamin A Substances 0.000 claims description 12
- 235000019166 vitamin D Nutrition 0.000 claims description 12
- 239000011710 vitamin D Substances 0.000 claims description 12
- 230000000202 analgesic effect Effects 0.000 claims description 11
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 11
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- 230000008338 local blood flow Effects 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- 239000010497 wheat germ oil Substances 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- 235000017663 capsaicin Nutrition 0.000 claims description 9
- 229960002504 capsaicin Drugs 0.000 claims description 9
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 8
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 claims description 8
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims description 8
- 235000021388 linseed oil Nutrition 0.000 claims description 8
- 239000000944 linseed oil Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 claims description 8
- 150000001483 arginine derivatives Chemical class 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- JXNRXNCCROJZFB-UHFFFAOYSA-N Di-Me ester-(2R, 3E)-Phytochromobilin Natural products NC(N)=NCCCC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-UHFFFAOYSA-N 0.000 claims description 3
- JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 108010053037 kyotorphin Proteins 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 22
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 12
- 102100024304 Protachykinin-1 Human genes 0.000 claims 11
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 11
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 11
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 11
- 229960003415 propylparaben Drugs 0.000 claims 11
- 229950011392 sorbitan stearate Drugs 0.000 claims 11
- 230000000779 depleting effect Effects 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 239000007952 growth promoter Substances 0.000 claims 8
- 239000006210 lotion Substances 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 8
- 239000002674 ointment Substances 0.000 claims 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- 229960003589 arginine hydrochloride Drugs 0.000 claims 4
- 239000004202 carbamide Substances 0.000 claims 4
- 239000003860 topical agent Substances 0.000 claims 4
- 235000019165 vitamin E Nutrition 0.000 claims 4
- 239000011709 vitamin E Substances 0.000 claims 4
- 229930003427 Vitamin E Natural products 0.000 claims 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 3
- 229940046009 vitamin E Drugs 0.000 claims 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 2
- 229940042585 tocopherol acetate Drugs 0.000 claims 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims 1
- AKGWUHIOEVNNPC-LURJTMIESA-N Arg-OEt Chemical group CCOC(=O)[C@@H](N)CCCNC(N)=N AKGWUHIOEVNNPC-LURJTMIESA-N 0.000 claims 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- 235000021307 Triticum Nutrition 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 229940124447 delivery agent Drugs 0.000 claims 1
- 150000001261 hydroxy acids Chemical class 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 229940100615 topical ointment Drugs 0.000 claims 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 10
- 210000004761 scalp Anatomy 0.000 abstract description 10
- 230000036407 pain Effects 0.000 abstract description 9
- 208000005230 Leg Ulcer Diseases 0.000 abstract description 6
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 33
- 230000000694 effects Effects 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 229960003121 arginine Drugs 0.000 description 18
- 235000009697 arginine Nutrition 0.000 description 18
- 238000009472 formulation Methods 0.000 description 7
- 210000003128 head Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 4
- 206010034568 Peripheral coldness Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 3
- 102400000096 Substance P Human genes 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 240000008574 Capsicum frutescens Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000001856 erectile effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- -1 sodium chloride Chemical class 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RVEWUBJVAHOGKA-WOYAITHZSA-N Arginine glutamate Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RVEWUBJVAHOGKA-WOYAITHZSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229960004246 arginine glutamate Drugs 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 108010052780 polyasparagine Proteins 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Plant Substances (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/936,189 | 1997-09-17 | ||
| US08/932,227 | 1997-09-17 | ||
| US08/936,189 US6207713B1 (en) | 1997-09-17 | 1997-09-17 | Topical and oral delivery of arginine to cause beneficial effects |
| US08/932,227 US7914814B2 (en) | 1997-09-17 | 1997-09-17 | Topical delivery of arginine of cause beneficial effects |
| US08/932,595 | 1997-09-17 | ||
| US08/936,188 | 1997-09-17 | ||
| US08/936,188 US5895658A (en) | 1997-09-17 | 1997-09-17 | Topical delivery of L-arginine to cause tissue warming |
| US08/932,595 US5922332A (en) | 1997-09-17 | 1997-09-17 | Topical delivery of arginine to overcome pain |
| PCT/US1998/019429 WO1999013717A1 (en) | 1997-09-17 | 1998-09-17 | A delivery of arginine to cause beneficial effects |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009084491A Division JP2009143968A (ja) | 1997-09-17 | 2009-03-31 | 有益な効果を奏するアルギニンの送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002515401A JP2002515401A (ja) | 2002-05-28 |
| JP2002515401A5 JP2002515401A5 (enExample) | 2008-07-10 |
| JP4352114B2 true JP4352114B2 (ja) | 2009-10-28 |
Family
ID=27506014
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000511359A Expired - Fee Related JP4352114B2 (ja) | 1997-09-17 | 1998-09-17 | 有益な効果を奏するアルギニンの投薬 |
| JP2009084491A Pending JP2009143968A (ja) | 1997-09-17 | 2009-03-31 | 有益な効果を奏するアルギニンの送達 |
| JP2014206221A Pending JP2015038119A (ja) | 1997-09-17 | 2014-10-07 | 有益な効果を奏するアルギニンの送達 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009084491A Pending JP2009143968A (ja) | 1997-09-17 | 2009-03-31 | 有益な効果を奏するアルギニンの送達 |
| JP2014206221A Pending JP2015038119A (ja) | 1997-09-17 | 2014-10-07 | 有益な効果を奏するアルギニンの送達 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP2158907B1 (enExample) |
| JP (3) | JP4352114B2 (enExample) |
| AT (1) | ATE456302T1 (enExample) |
| AU (1) | AU737199B2 (enExample) |
| CA (1) | CA2303394C (enExample) |
| DE (1) | DE69841481D1 (enExample) |
| ES (2) | ES2340450T3 (enExample) |
| WO (1) | WO1999013717A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
| US7629384B2 (en) | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
| US6284797B1 (en) * | 1999-04-12 | 2001-09-04 | Donald A. Rhodes | Topical treatment of pain and to promote healing |
| JP2000327560A (ja) * | 1999-05-18 | 2000-11-28 | Noevir Co Ltd | 入浴剤組成物 |
| FR2794974B1 (fr) * | 1999-06-16 | 2001-08-17 | Exsymol Sa | Composition cosmetique pour l'amincissement a base de l-arginine, d'un analogue de l-arginine ou d'un de leurs derives, applicable par voie topique |
| US6322493B1 (en) * | 1999-07-01 | 2001-11-27 | 40 J's Llc | Expanded clitoral sensitizing compounds with methods and apparatus for the delivery of these compounds |
| JP4681132B2 (ja) * | 2001-01-29 | 2011-05-11 | 味の素株式会社 | 一酸化窒素合成酵素産生促進剤および化粧料若しくは医薬組成物 |
| DE10113446A1 (de) * | 2001-03-19 | 2002-09-26 | Schwarzkopf Gmbh Hans | Haarbehandlungsmittel mit Betainen |
| JP4229842B2 (ja) * | 2002-02-22 | 2009-02-25 | ルバンス セラピュティックス インク． | Ｌ−アルギニンオリゴマーを含む化粧品処方 |
| US7326717B2 (en) | 2003-05-06 | 2008-02-05 | L'oreal | Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof |
| AU2005216192B2 (en) * | 2004-02-23 | 2010-11-04 | Strategic Science & Technologies, Llc | Topical delivery of a nitric oxide donor to improve body and skin appearance |
| JP2005281272A (ja) * | 2004-03-31 | 2005-10-13 | Suntory Ltd | 末梢血流改善剤 |
| JP4837896B2 (ja) * | 2004-03-31 | 2011-12-14 | 焼津水産化学工業株式会社 | 精力増強剤 |
| JP4836044B2 (ja) * | 2004-04-02 | 2011-12-14 | 味の素株式会社 | 経口アミノ酸ニキビ治療剤 |
| AU2005235308B2 (en) | 2004-04-19 | 2011-12-01 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| AU2012201048B2 (en) * | 2004-04-19 | 2013-06-06 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| EP2417978A1 (en) | 2004-04-19 | 2012-02-15 | Strategic Science & Technologies, LLC | Beneficial effects of increasing local blood flow |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| JP2006169406A (ja) * | 2004-12-16 | 2006-06-29 | Fuji Latex Kk | コンドーム用水性潤滑剤および当該潤滑剤を塗布したコンドーム |
| JP2008179540A (ja) * | 2005-01-07 | 2008-08-07 | Noevir Co Ltd | 細胞分化、発生、増殖を制御する物質および該物質を含む細胞分化・発生・増殖調節剤 |
| FR2883167B1 (fr) * | 2005-03-18 | 2009-07-10 | Oreal | Composition de soin capillaire et/ou des cils contenant de l'aminexil en association avec un vasodilatateur, destinee a stimuler la croissance des cheveux et/ou des cils et/ou freiner leur chute, ses utilisations |
| WO2006097359A1 (en) * | 2005-03-18 | 2006-09-21 | L'oréal | Hair and/or eyelash care composition containing aminexil in combination with an agent for promoting the no production and uses thereof |
| US8445536B2 (en) | 2005-03-31 | 2013-05-21 | Ajinomoto Co., Inc. | Arginine-containing compositions and methods for increasing blood flow using same |
| JP5046174B2 (ja) * | 2005-03-31 | 2012-10-10 | 味の素株式会社 | アルギニン含有血流増加用組成物 |
| JP5572318B2 (ja) | 2005-12-30 | 2014-08-13 | ルバンス セラピュティックス インク． | 局所投与用アルギニンヘテロマー |
| WO2008089435A1 (en) * | 2007-01-18 | 2008-07-24 | Wyeth | Methods of identifying pain modulators |
| WO2009036771A1 (es) * | 2007-09-21 | 2009-03-26 | Pharmabrand S.A. | Composición de polisacáridos mucilaginosos, derivados de aloe barbadensis, en combinación con liposomas, procedimiento de obtención y uso de la misma como fotoprotectora, antiacné, regeneradora de la epidermis e hidratante |
| FR2929118B1 (fr) * | 2008-03-28 | 2010-05-07 | Oreal | Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| WO2010151240A1 (en) | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
| WO2010151241A1 (en) * | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
| AU2015203547B2 (en) * | 2009-06-24 | 2017-05-18 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
| DK2658551T3 (da) | 2010-12-29 | 2020-09-21 | Strategic Science & Tech Llc | Behandling af erektil dysfunktion og andre indikationer |
| CN105878172A (zh) | 2010-12-29 | 2016-08-24 | 战略科学与技术有限责任公司 | 治疗变态反应和其它适应症的系统和方法 |
| WO2014152280A1 (en) | 2013-03-15 | 2014-09-25 | Strategic Science & Technologies, Llc | Transdermal formulations of fluticasone |
| EP2968130A1 (en) | 2013-03-15 | 2016-01-20 | Strategic Science & Technologies, LLC | Transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors |
| US10894024B2 (en) * | 2014-12-08 | 2021-01-19 | Synaptamine, Inc. | Anti-RDS compounds and method of manufacture and administration thereof to induce dopamine homeostatis |
| WO2016112201A1 (en) | 2015-01-07 | 2016-07-14 | Strategic Science & Technologies, Llc | Techniques and systems for transdermal delivery involving treatment of psoriasis, skin cancer, and other indications |
| MY176129A (en) * | 2015-08-06 | 2020-07-24 | Coats Agri Aloe Llc | Compositions and methods to increase plant yield |
| GB201620701D0 (en) * | 2016-12-06 | 2017-01-18 | Glaxosmithkline Consumer Healthcare (Uk) Ip Ltd | Novel composition |
| US10624907B2 (en) * | 2017-04-12 | 2020-04-21 | Performance Labs PTE. LTD. | Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement |
| CN110870914A (zh) * | 2018-08-31 | 2020-03-10 | 成都夸常奥普医疗科技有限公司 | 氨基酸类营养素的应用以及包含它的药物组合物 |
| JP7642955B2 (ja) * | 2021-02-04 | 2025-03-11 | 株式会社ファンケル | 嗅覚受容体発現促進用組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5940M (enExample) * | 1966-10-18 | 1968-04-08 | ||
| FR2602678B1 (fr) * | 1986-08-13 | 1992-06-05 | Drouault Guy | Composition pharmaceutique aqueuse a base de sels de magnesium, sodium et potassium pour la regulation des circulations locales |
| DE69022678T2 (de) * | 1989-10-17 | 1996-03-21 | Merck & Co Inc | S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential. |
| JPH045231A (ja) * | 1990-04-20 | 1992-01-09 | Morishita Pharmaceut Co Ltd | 慢性痛用鎮痛剤 |
| JPH0789862A (ja) * | 1990-05-29 | 1995-04-04 | Toyobo Co Ltd | 抗炎症性、免疫抑制性および鎮痛性組成物、およびこれらの組成物を用いた自己免疫疾患の治療方法 |
| DE4100975A1 (de) * | 1991-01-15 | 1992-07-16 | Weuffen Wolfgang | Kosmetische oder pharmazeutische zubereitungen zur verbesserung der haarqualitaet und foerderung des haarwachstums |
| US5852058A (en) * | 1993-06-11 | 1998-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
| DE4338793A1 (de) * | 1993-11-12 | 1995-05-18 | Froelich Juergen C | L-Arginin und Analoge als Thrombozytenaggregationshemmer |
| DE4341000A1 (de) * | 1993-12-02 | 1995-06-08 | Beiersdorf Ag | Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen |
| US5594032A (en) * | 1994-11-10 | 1997-01-14 | Gonzalez-Cadavid; Nestor F. | Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA |
| US5595753A (en) * | 1995-04-14 | 1997-01-21 | President And Fellows Of Harvard College | Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract |
| US5734080A (en) * | 1995-09-22 | 1998-03-31 | Anihealth Corporation | Reaction product of arginine and p-aminobenzoic acid, cosmetic, and human and animal health compositions thereof |
-
1998
- 1998-09-17 ES ES98946099T patent/ES2340450T3/es not_active Expired - Lifetime
- 1998-09-17 CA CA2303394A patent/CA2303394C/en not_active Expired - Fee Related
- 1998-09-17 AU AU93186/98A patent/AU737199B2/en not_active Ceased
- 1998-09-17 JP JP2000511359A patent/JP4352114B2/ja not_active Expired - Fee Related
- 1998-09-17 EP EP09014985.7A patent/EP2158907B1/en not_active Expired - Lifetime
- 1998-09-17 ES ES09014985.7T patent/ES2549329T3/es not_active Expired - Lifetime
- 1998-09-17 DE DE69841481T patent/DE69841481D1/de not_active Expired - Lifetime
- 1998-09-17 WO PCT/US1998/019429 patent/WO1999013717A1/en not_active Ceased
- 1998-09-17 EP EP98946099A patent/EP1041880B1/en not_active Expired - Lifetime
- 1998-09-17 AT AT98946099T patent/ATE456302T1/de not_active IP Right Cessation
-
2009
- 2009-03-31 JP JP2009084491A patent/JP2009143968A/ja active Pending
-
2014
- 2014-10-07 JP JP2014206221A patent/JP2015038119A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU9318698A (en) | 1999-04-05 |
| JP2015038119A (ja) | 2015-02-26 |
| EP1041880B1 (en) | 2010-01-27 |
| JP2002515401A (ja) | 2002-05-28 |
| EP1041880A4 (en) | 2006-04-12 |
| ES2340450T3 (es) | 2010-06-02 |
| JP2009143968A (ja) | 2009-07-02 |
| EP2158907A2 (en) | 2010-03-03 |
| EP2158907B1 (en) | 2015-08-05 |
| CA2303394A1 (en) | 1999-03-25 |
| CA2303394C (en) | 2011-12-20 |
| WO1999013717A1 (en) | 1999-03-25 |
| ATE456302T1 (de) | 2010-02-15 |
| EP2158907A3 (en) | 2010-05-26 |
| WO1999013717B1 (en) | 1999-04-22 |
| AU737199B2 (en) | 2001-08-09 |
| EP1041880A1 (en) | 2000-10-11 |
| ES2549329T3 (es) | 2015-10-27 |
| DE69841481D1 (de) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4352114B2 (ja) | 有益な効果を奏するアルギニンの投薬 | |
| JP2002515401A5 (enExample) | ||
| US6458841B2 (en) | Topical and oral delivery of arginine to cause beneficial effects | |
| US7629384B2 (en) | Topical delivery of L-arginine to cause beneficial effects | |
| US5895658A (en) | Topical delivery of L-arginine to cause tissue warming | |
| US8603519B2 (en) | Topical delivery of L-arginine to cause beneficial effects | |
| JP5630942B2 (ja) | 不利な生物物理学的環境によりもたらされる有益な物質の経皮送達 | |
| US7871647B1 (en) | Topical treatment of neuropathy | |
| US20160101139A1 (en) | Topical treatment for use as a sleep aid | |
| EP2691103B1 (en) | Method for treating disorders of the skin | |
| US7442690B2 (en) | Topical treatment for psoriasis | |
| US12048729B2 (en) | Composition for transdermal delivery of glutathione | |
| US5576329A (en) | Method for treating tendon or joint inflammation with papaverine HCL | |
| US20160101141A1 (en) | Topical Treatment of Sports Related Injuries | |
| US10548830B2 (en) | Composition for transdermal delivery of glutathione | |
| US10314779B2 (en) | Composition for transdermal delivery of glutathione | |
| WO2017201624A1 (en) | Composition for transdermal delivery of glutathione | |
| CA2551690A1 (en) | Compositions for use with skin | |
| HK1219872A1 (zh) | 新的皮膚護理製劑 | |
| CA2835840A1 (en) | Beneficial effects of increasing local blood flow | |
| HK1188943A (en) | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050419 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050419 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050421 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080220 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080227 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080520 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080922 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080924 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090331 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090408 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090602 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090629 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120807 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120807 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130807 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |